Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 0.58 |
| ▸ | DRD2 | P14416 | 11/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12314095 | 1.00 | DRD3 (0.58) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL25652855 | 0.85 | DRD2 (0.52) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL4875328 | 0.78 | DRD2 (0.67) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL14289423 | 0.78 | DRD3 (0.69) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL22210214 | 0.78 | DRD3 (0.55) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL26870356 | 0.78 | DRD3 (0.73) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL1764998 | 0.77 | DRD2 (0.45) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL1764996 | 0.77 | DRD2 (0.45) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL4669800 | 0.76 | SLC18A3 (0.51) | DRD3DRD2 | |
| SCHEMBL12314083 | 0.76 | OPRM1 (0.64) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518966-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8268863-B2 | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8211894-B2 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110144152-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7947710-B2 | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7902221-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7691878-B2 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062332-A1 | Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists | THERAVANCE, INC | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062332-A1 | Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD3 193/4885DRD2 100/4885CYP2D6 246/4885 |
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRL1, OPRK1 | DRD3 192/4885DRD2 156/4885CYP2D6 296/4885 |
| US-20110144152-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD3 193/4885DRD2 100/4885CYP2D6 246/4885 |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD3 168/4885DRD2 117/4885CYP2D6 169/4885 |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | DRD3 195/4885DRD2 154/4885CYP2D6 256/4885 |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD3 168/4885DRD2 117/4885CYP2D6 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.